A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.
Specifications
- Classify
- Protein therapeutics that interfere with a molecule or organism: Transplantation
- Therapeutic
- Basiliximab
- Trade Name
- Simulect
- Function
- Chimeric (human/mouse) igG1 that blocks cellular immune response in graft rejection by binding the alpha chain of cD25 (iL2 receptor) and thereby inhibiting the iL2-mediated activation of lymphocytes
- Examples of Clinical Use
- Prophylaxis against allograft rejection in renal transplant patients receiving an immunosuppressive regimen including cyclosporine and corticosteroids
References
- Synonyms
- chimeric mouse-human antiCD25, Ig gamma-1 chain C region
- UniProt
- P01857
- Genbank
- J00228
For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: